Human IL-23 alpha & Mouse IL-12 beta Heterodimer Protein, produced by co-expression of IL-23 alpha and IL-12 beta, has a calculated MW of 19.5 kDa (IL-23 alpha) and 35.8 kDa (IL-12 beta). Subunit IL-23 alpha is fused with a polyhistidine tag at the N-terminus and subunit IL-12 beta contains no tag. The predicted N-terminus is His (IL23A) & Met 23 (IL12B). The reducing (R) protein migrates as 20 kDa (IL-23 alpha) and 45-50 kDa (IL-12 beta) respectively due to glycosylation.
Spezies: Human
Wirt: Human Cells
Recombinant
Greater than 95 % as determined by reducing SDS-PAGE.
ELISA, MS, SDS, WB
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Buffer
PBS, pH 7.4
Handhabung
Please avoid repeated freeze-thaw cycles.
Lagerung
-20 °C
Target
IL12A & IL27B
Andere Bezeichnung
IL23A & IL12B
Hintergrund
Interleukin-23 subunit alpha (IL-23 alpha) can associates with IL12B to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory rather than naive T-cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune inflammation and thus may be responsible for autoimmune inflammatory diseases and may be important for tumorigenesis.